Terms: = Ovarian cancer AND KLF6, RP11-184A2_1, 1316, ENSG00000067082, ST12, DKFZp686N0199, CPBP, Zf9, COPEB, ZF9, PAC1, GBF, BCD1 AND Treatment
12546 results:
1. Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.
Wang Y; Chen X; Chen Q; Liu T; Wu Y; Huang L; Chen Y
J Cell Mol Med; 2024 May; 28(9):e18371. PubMed ID: 38686496
[TBL] [Abstract] [Full Text] [Related]
2. A Novel Non-Psychoactive Fatty Acid from a Marine Snail,
Vijayaraghavan CS; Raman LS; Surenderan S; Kaur H; Chinambedu MD; Thyagarajan SP; Gnanambal Krishnan ME
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675558
[TBL] [Abstract] [Full Text] [Related]
3. TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of MCL-1.
Cai Y; Li Y; Xu Y; Yang W; Huang M
FASEB J; 2024 Apr; 38(8):e23625. PubMed ID: 38661028
[TBL] [Abstract] [Full Text] [Related]
4. Exceptional lymph node recurrence of an unusual ovarian tumor 16 years later: a case report.
Sakhri S; Slimane M; Bouaziz H; Khessairi N; Boujelbene N; Ben Dhiab T
J Med Case Rep; 2024 Apr; 18(1):217. PubMed ID: 38654310
[TBL] [Abstract] [Full Text] [Related]
5. Granulosa cell tumor of the ovary: a series of 6 cases.
da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
[TBL] [Abstract] [Full Text] [Related]
6. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
7. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
8. Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.
Li N; Jin S; Wu J; Ji H; Du C; Liu B
PLoS One; 2024; 19(4):e0299504. PubMed ID: 38635517
[TBL] [Abstract] [Full Text] [Related]
9. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
[TBL] [Abstract] [Full Text] [Related]
10. Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.
Elshami M; Jaber I; Alser M; Al-Slaibi I; Jabr H; Ubaiat S; Tuffaha A; Khader S; Khraishi R; Arafeh ZA; Al-Madhoun S; Alqattaa A; Yaseen A; El Hadi AA; Barhoush O; Hijazy M; Eleyan T; Alser A; Hziema AA; Shatat A; Almakhtoob F; Mohamad B; Farhat W; Abuamra Y; Mousa H; Adawi R; Musallam A; Albarqi SI; Abu-El-Noor N; Bottcher B
BMC Public Health; 2024 Apr; 24(1):1027. PubMed ID: 38609950
[TBL] [Abstract] [Full Text] [Related]
11. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
12. Construction and analysis of competitive endogenous RNA networks and prognostic models associated with ovarian cancer based on the exoRBase database.
Chen Z; Wang C; Ding J; Yu T; Li N; Ye C
PLoS One; 2024; 19(4):e0291149. PubMed ID: 38603733
[TBL] [Abstract] [Full Text] [Related]
13. Olaparib Addition to Maintenance Bevacizumab Therapy in ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
[TBL] [Abstract] [Full Text] [Related]
14. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
15. Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer.
Kallio HM; Savolainen K; Virtanen T; Ryyppö L; Selin H; Martikainen P; Staff S; Kivinummi K; Sipola J; Vuorinen J; Nikkola J; Nykter M; Auranen A; Annala M
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38580393
[TBL] [Abstract] [Full Text] [Related]
16. Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
Wu Z; Zhang Q; Jin Y; Zhang X; Chen Y; Yang C; Tang X; Jiang H; Wang X; Zhou X; Yu F; Wang B; Guan M
BMC Cancer; 2024 Apr; 24(1):411. PubMed ID: 38566028
[TBL] [Abstract] [Full Text] [Related]
17. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
Yuan H; Li N; Wu L; Yao H
J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
[TBL] [Abstract] [Full Text] [Related]
18. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E; Huang TT; Nair JR; Zurcher G; McCoy A; Nousome D; Radke MR; Swisher EM; Lipkowitz S; Ibanez K; Donohue D; Malys T; Lee MJ; Redd B; Levy E; Rastogi S; Sato N; Trepel JB; Lee JM
Nat Commun; 2024 Mar; 15(1):2805. PubMed ID: 38555285
[TBL] [Abstract] [Full Text] [Related]
19. Epithelial ovarian cancer in younger age versus older age groups: Survival and clinicopathological features.
Kongkamsuan W; Boonyapipat S
J Cancer Res Ther; 2024 Jan; 20(1):363-368. PubMed ID: 38554347
[TBL] [Abstract] [Full Text] [Related]
20. Characteristics of patients with late recurrence endometrial cancer.
Çakır İ; Gülseren V; Özdemir İA; Abacı H; Talu ECK; Çakır ZE; Ata C; Kuru O; Gökçü M; Sancı M; Güngördük K
J Cancer Res Ther; 2024 Jan; 20(1):232-237. PubMed ID: 38554326
[TBL] [Abstract] [Full Text] [Related]
[Next]
